Validated points and issues to be addressed by ongoing trials
| Validated points . |
|---|
| Novel imaging techniques are more sensitive than skeletal survey and are correctly distinguishing SMM from MM from SP |
| WBLDCT is the minimal requirement for detection of lytic lesions |
| MRI is the best imaging modality for assessment of BM involvement |
| PET/CT is the preferred technique for detection of EMD |
| FLs display prognostic significance for PFS and OS |
| Functional imaging techniques are required for evaluation of metabolic response to therapy |
| PET/CT is the preferred technique to evaluate MRD after therapy |
| MRD by NGS or NGF and PET/CT are complementary |
| Open issues |
| Standardization and guidelines for acquisition, interpretation, and reporting of all 3 imaging techniques |
| Correlation of new PET tracers with outcomes |
| Correlation of DWI MRI with outcomes |
| Prospective comparison of PET/CT and functional MRI after therapy |
| Optimal timing of PET/CT and DWI MRI for evaluation of response and during follow-up |
| Concordance between imaging and NGS/NGF MRD negativity, at different sensitivity thresholds |
| Contribution of imaging to the definition and loss of sustained MRD negativity |
| Impact of MRD assessment on treatment strategies |
| Validated points . |
|---|
| Novel imaging techniques are more sensitive than skeletal survey and are correctly distinguishing SMM from MM from SP |
| WBLDCT is the minimal requirement for detection of lytic lesions |
| MRI is the best imaging modality for assessment of BM involvement |
| PET/CT is the preferred technique for detection of EMD |
| FLs display prognostic significance for PFS and OS |
| Functional imaging techniques are required for evaluation of metabolic response to therapy |
| PET/CT is the preferred technique to evaluate MRD after therapy |
| MRD by NGS or NGF and PET/CT are complementary |
| Open issues |
| Standardization and guidelines for acquisition, interpretation, and reporting of all 3 imaging techniques |
| Correlation of new PET tracers with outcomes |
| Correlation of DWI MRI with outcomes |
| Prospective comparison of PET/CT and functional MRI after therapy |
| Optimal timing of PET/CT and DWI MRI for evaluation of response and during follow-up |
| Concordance between imaging and NGS/NGF MRD negativity, at different sensitivity thresholds |
| Contribution of imaging to the definition and loss of sustained MRD negativity |
| Impact of MRD assessment on treatment strategies |
NGF, next-generation flow cytometry; NGS, next-generation sequencing.